What an outsourcing facility registration commits a facility to

It is an election, not an assessment

The statute defines an outsourcing facility as a facility at one geographic location that is engaged in compounding sterile drugs, "has elected to register" as one, and complies with all of the section's requirements.

The agency uses the same word on its own page about compounding law, describing the category as a new, voluntary one created by the legislation that followed a fatal national outbreak.

That matters for how a reader treats the absence of the badge. A compounder that is not registered has not been examined and turned down. It has not entered a category that nothing obliged it to enter.

Two further clauses in the same definition are routinely skipped. Such a facility "is not required to be a licensed pharmacy," and it "may or may not obtain prescriptions for identified individual patients."

A different exemption, and one section conspicuously missing

Both compounding sections open the same way, by naming the requirements that will not apply. The lists are not the same list.

The outsourcing facility section lifts the adequate-directions labeling provision, the section requiring an approved application before marketing, and a supply-chain tracing provision. The manufacturing-practice provision is not among them.

The agency states the consequence directly: unlike compounders operating under the traditional section, outsourcing facilities are subject to current good manufacturing practice requirements.

This is the substantive difference between the two categories, and it is the one worth carrying into any comparison. It is a rule about how a preparation is made. It is not a review of whether the preparation works.

Eleven conditions, and the eleventh closes the loop

The exemption is conditional on every paragraph of a numbered list, and the list is longer than most summaries of it.

Registration and reporting. Restrictions on which bulk substances may be used. A monograph standard for other ingredients. The prohibition list of products withdrawn or removed as unsafe or not effective. A bar on drugs that are essentially copies of approved drugs. The list of products presenting demonstrable difficulties for compounding. Comparable controls where a drug carries a formal risk-management program. A prohibition on wholesaling. Payment of fees. A detailed labeling requirement.

Then the eleventh, which is the one that gives the category its shape: the drug is compounded in a facility "in which the compounding of drugs occurs only in accordance with this section."

A facility cannot hold the badge for part of its output and work outside the section for the rest. The condition is written about the facility, not about the batch.

The label a buyer could actually read

One condition is unusually concrete, and it is the one that reaches a person holding a vial.

The label has to carry the statement "This is a compounded drug," or a comparable statement specified by the agency that prominently identifies it as one. It has to carry the facility's name, address and phone number.

Then a list. Lot or batch number, established name, dosage form and strength, and the statement of quantity or volume. The date the drug was compounded, the expiration date, and storage and handling instructions. A national drug code number if one is available, and the statement "Not for resale." Finally, the active and inactive ingredients by established name, with the quantity or proportion of each.

Where the drug is supplied other than against a prescription for an identified patient, the label also carries the words "Office Use Only." The container the individual units come out of has to carry an adverse-event reporting address and phone number.

What the public register shows, and what it withholds

The statute requires the agency to publish a list of registered facilities, and it specifies what goes in it. The name of each facility, the state it is in, whether it compounds from bulk drug substances, and whether that compounding is for sterile or nonsterile drugs.

The published table goes further than the statutory minimum. Its columns include the initial and most recent registration dates and the date of the last inspection. They also record whether an inspection observation form was issued, whether a recall was conducted, and the action based on the last inspection. A final column states whether the facility intends to compound sterile drugs from bulk substances.

One of the values that appears in the inspection column is "Not yet inspected." Registration and inspection are separate events, and the table is explicit enough to let a reader see which has happened.

What the register does not show is what a facility makes. Facilities report their products to the agency twice a year. The statute says those reports "shall be exempt from inspection" by the public, unless the agency finds that withholding them would be inconsistent with protecting public health.

Inspection, and the exemption that is taken away

The inspection duty is written into the same section, in two clauses that are easy to read past.

Outsourcing facilities "shall be subject to inspection" under the general inspection section of the Act, and they "shall not be eligible for the exemption under section 374(a)(2)(A)."

That second clause is the interesting one. There is a carve-out in the inspection section that a qualifying pharmacy can rely on, and registering as an outsourcing facility removes it by name. The category swaps a shelter for a schedule.

The schedule is risk-based, and the statute lists the factors. Compliance history, and the record and nature of recalls linked to the facility. The inherent risk of the drugs it compounds. Its inspection frequency and history, including whether it has been inspected in the last four years. And whether it registered as a facility intending to compound a drug on the shortage list.

Two things the badge still does not mean

The first is approval. Nothing in the section reviews a product. A facility can satisfy every one of the eleven conditions and still be making a drug that no agency has evaluated for safety, effectiveness or quality.

The second is a substitute for a state license. The section's final subsection says paying the federal fee does not relieve a facility that is licensed as a pharmacy in a state requiring pharmacy licensing fees of its obligation to pay them.

The definition already said such a facility need not be a licensed pharmacy at all. Reading the two together, the federal category and the state license are separate questions with separate answers, and one does not report the other.

A seller naming a compounding category has told you which rulebook applies. It has not told you that anyone applied it, which is what the inspection column on the public register exists to answer.

Sources

Each document below is named as it names itself, with the date printed on that document rather than the day it was read.

1. Title 21 United States Code section 353b, Outsourcing facilities, text as published with the currency line "Text contains those laws in effect on September 5, 2026" — Office of the Law Revision Counsel, U.S. House of Representatives, September 2026
2. Title 21 United States Code section 374, Inspection, including the paragraph (a)(2) exceptions that section 353b withdraws from outsourcing facilities by name — Office of the Law Revision Counsel, U.S. House of Representatives, September 2026
3. Registered Outsourcing Facilities, the published table of facilities registered under section 503B and their inspection history, carrying its own updated-as-of line — U.S. Food and Drug Administration, August 2026
4. Human Drug Compounding Laws, stating that section 503B established a voluntary category of compounders and that outsourcing facilities, unlike compounders under section 503A, are subject to current good manufacturing practice requirements — U.S. Food and Drug Administration, December 2024